AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24777150 — intervention group
Group type: COMPARATOR
Intervention: High-dose oral esomeprazole at a dose of 40 mg every 12 h (ORP group)
Number of subjects: 244
Study 23126645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined simvastatin 40 mg and ezetimibe 10 mg daily
Number of subjects: 1418
Study 23126645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1418
Study 20043083 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (NSAID) for 3 days before surgery
Number of subjects: 23
Study 20043083 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 23
Study 20043083 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (NSAID)
Number of subjects: 23
Study 16936703 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 34
Study 16936703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 34
Study 16260201 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177
Study 16260201 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study 11300382 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose L-arginine (n=10)
Number of subjects: 35
Study 11300382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose L-arginine (n=10)
Number of subjects: 35
Study 11300382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 35
Study 9448657 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (6-16 mg/day)
Number of subjects: 513
Study 9448657 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (2 mg/day)
Number of subjects: 513
Study 9448657 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 513
Study 9448657 — intervention group
Group type: COMPARATOR
Intervention: haloperidol (20 mg/day)
Number of subjects: 513
Study 9448657 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 513
Study 7939440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection therapy with papaverine/phentolamine (n = 172 evaluable)
Number of subjects: 603
Study 7939440 — intervention group
Group type: COMPARATOR
Intervention: Venous surgery (n = 134 evaluable)
Number of subjects: 603
Study 3145948 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of flurazepam taken the night before surgery
Number of subjects: 20
Study 3145948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3145948 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 20
Study 29493385 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) added to standard pegylated interferon and ribavirin (PEG‐IFN/RBV)
Number of subjects: 31
Study 29493385 — intervention group
Group type: COMPARATOR
Intervention: Standard pegylated interferon and ribavirin (PEG‐IFN/RBV) alone
Number of subjects: 31
Study 28679180 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and Calendula suppositories (350 mg Curcumin, 80 mg Calendula, 1 suppository/day for 1 month)
Number of subjects: 60
Study 28679180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 suppository/day for 1 month)
Number of subjects: 60
Study 26039929 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-selected care buddy (PSCB)
Number of subjects: 1209
Study 26039929 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 1209
Study 23943213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic cerebral autoregulation (CA) measured by transfer function phase on day 5
Number of subjects: 26
Study 23943213 — intervention group
Group type: COMPARATOR
Intervention: Dynamic CA measured by gain
Number of subjects: 26
Study 23943213 — intervention group
Group type: COMPARATOR
Intervention: Dynamic CA measured by phase
Number of subjects: 26
Study 23943213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CA measured by phase on day 1
Number of subjects: 26
Study 21288520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported smoking status
Number of subjects: 91
Study 21288520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day
Number of subjects: 91
Study 18186996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulb syringe self-treatment with ear drops and instructions
Number of subjects: 237
Study 18186996 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation by GP or practice nurse with ear drops
Number of subjects: 237
Study 18186996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulb syringe self-treatment
Number of subjects: 237
Study 18186996 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation
Number of subjects: 237
Study 17001115 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Dot class Ag/AgCl electrodes type 2222 (conductive area/total area: 2.00/10.24 cm2)
Number of subjects: 12
Study 17001115 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Dot class Ag/AgCl electrodes type 2271 (conductive area/total area: 2.54/29.64 cm2)
Number of subjects: 12
Study 17001115 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Dot class Ag/AgCl electrodes type 2660 (conductive area/total area: 11.64/11.64 cm2)
Number of subjects: 12
Study 14693310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a (IFNβ‐1a) 30 μg IM once weekly
Number of subjects: 91
Study 14693310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 10595879 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided cricothyrotomy technique
Number of subjects: 15
Study 10595879 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical cricothyrotomy technique
Number of subjects: 15
Study 8767567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (10 Hz)
Number of subjects: 7
Study 8767567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (50 Hz)
Number of subjects: 7
Study 8767567 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (0.2 Hz)
Number of subjects: 7
Study 8767567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (10 Hz and 50 Hz)
Number of subjects: 7
Study 1749978 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural analgesia (IPA)
Number of subjects: 39
Study 1749978 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 39
Study 1749978 — intervention group
Group type: COMPARATOR
Intervention: Intravenous narcotics
Number of subjects: 39
Study 6195981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 1,000 ml
Number of subjects: 20
Study 6195981 — intervention group
Group type: COMPARATOR
Intervention: 25% albumin 200 ml
Number of subjects: 20
Study 31242512 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus GG)
Number of subjects: 60
Study 31242512 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 29496058 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) lymphangiography, 2.5mg injected submucosally and subdermally
Number of subjects: 22
Study 27336154 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-supplemented yogurt (VDY) drink
Number of subjects: 0
Study 27336154 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt
Number of subjects: 0
Study 24556626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (platinum-based regimens)
Number of subjects: 535
Study 22878381 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses (CLs)
Number of subjects: 30
Study 22878381 — intervention group
Group type: COMPARATOR
Intervention: Monofocal contact lenses (CLs)
Number of subjects: 30
Study 20507560 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved dining atmosphere, greater food choice, extended restaurant hours, readily available snacks and drinks machines
Number of subjects: 120
Study 20507560 — intervention group
Group type: COMPARATOR
Intervention: Control homes maintained previous food and drink provision system
Number of subjects: 120
Study 18257182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acup‐moxibustion treatment
Number of subjects: 120
Study 18257182 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 50 mg Clomiphene
Number of subjects: 120
Study 15766996 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg once daily)
Number of subjects: 687
Study 15766996 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with every levodopa dose)
Number of subjects: 687
Study 15766996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 12829862 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated patients
Number of subjects: 2885
Study 12829862 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 2885
Study 12829862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medically and surgically treated patients
Number of subjects: 2885
Study 12829862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhages (PTI, ICH, SAH)
Number of subjects: 2885
Study 10888476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (100,000 I.U.)
Number of subjects: 15
Study 10888476 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy
Number of subjects: 15
Study 7725125 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (six sessions including support, problem-solving, and coping skills)
Number of subjects: 80
Study 7725125 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 80
Study 2040104 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 0.5% gel (5 mg q.i.d.)
Number of subjects: 200
Study 2040104 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 200
Study 7325344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of peridural anaesthesia and neuroleptanalgesia (PDA/NLA)
Number of subjects: 20
Study 7325344 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia with intubation
Number of subjects: 20
Study 6404603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol
Number of subjects: 43
Study 6404603 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 43
Study 30248102 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 250
Study 30248102 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 250
Study 26840669 — intervention group
Group type: EXPERIMENTAL
Intervention: Oromotor stimulation along with routine care (n=25)
Number of subjects: 51
Study 24734244 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized instruction
Number of subjects: 38
Study 24734244 — intervention group
Group type: COMPARATOR
Intervention: Video-based instruction
Number of subjects: 38
Study 22235969 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 178
Study 22235969 — intervention group
Group type: COMPARATOR
Intervention: Control group (mock treatment)
Number of subjects: 178
Study 20070642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-panel (DP) methodology
Number of subjects: 200
Study 20070642 — intervention group
Group type: COMPARATOR
Intervention: Forward-backward (FB) methodology
Number of subjects: 200
Study 20070642 — intervention group
Group type: EXPERIMENTAL
Intervention: Both versions (FB and DP)
Number of subjects: 200
Study 19099547 — intervention group
Group type: COMPARATOR
Intervention: 0.5-2% chitin-glucan applied twice daily
Number of subjects: 33
Study 19099547 — intervention group
Group type: COMPARATOR
Intervention: 1.5% chitin-glucan formulation applied twice daily
Number of subjects: 33
Study 15780532 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 95
Study 15780532 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 95
Study 15780532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 95
Study 12417278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C administration
Number of subjects: 31
Study 12417278 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 31
Study 12417278 — intervention group
Group type: COMPARATOR
Intervention: Maximal exercise (Control)
Number of subjects: 31
Study 12417278 — intervention group
Group type: COMPARATOR
Intervention: Submaximal exercise
Number of subjects: 31
Study 10356076 — intervention group
Group type: EXPERIMENTAL
Intervention: (n-3) fatty acid supplementation (approximately 5.2 g (n-3) fatty acids)
Number of subjects: 11
Study 10356076 — intervention group
Group type: COMPARATOR
Intervention: Control oil period (COP)
Number of subjects: 11
Study 10356076 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (BLP)
Number of subjects: 11
Study 10356076 — intervention group
Group type: EXPERIMENTAL
Intervention: (n-3) fatty acid supplementation
Number of subjects: 11
Study 7594152 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-month duration)
Number of subjects: 197
Study 7594152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 197
Study 1723455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg once daily
Number of subjects: 141
Study 1723455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 7472173 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (Luminal) 10 mg/kg orally
Number of subjects: 41
Study 7472173 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (Luminal) 15 mg/kg intramuscularly
Number of subjects: 41
Study 7472173 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (Luminal) 5 mg/kg orally or intramuscularly
Number of subjects: 41
Study 31380297 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic administration
Number of subjects: 32
Study 28366435 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab 300mg
Number of subjects: 218
Study 28366435 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab 150mg
Number of subjects: 218
Study 28366435 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 218
Study 28366435 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 218
Study 25851155 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitin microparticles (CP)
Number of subjects: 14
Study 25851155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25851155 — intervention group
Group type: COMPARATOR
Intervention: Lipopolysaccharide (LPS)
Number of subjects: 14
Study 23380438 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM‐151 (10 mg/kg)
Number of subjects: 8
Study 23380438 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM‐151
Number of subjects: 8
Study 21713778 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib adjuvant therapy
Number of subjects: 90
Study 21713778 — intervention group
Group type: COMPARATOR
Intervention: Follow-up alone (Control)
Number of subjects: 90
Study 21713778 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation Imatinib treatment
Number of subjects: 90
Study 21713778 — intervention group
Group type: COMPARATOR
Intervention: Interruption treatment (Control)
Number of subjects: 90
Study 18832751 — intervention group
Group type: EXPERIMENTAL
Intervention: rHDL (80 mg/kg given over 4 hours)
Number of subjects: 20
Study 18832751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16485185 — intervention group
Group type: EXPERIMENTAL
Intervention: 2500 units of Factor XIII
Number of subjects: 75
Study 16485185 — intervention group
Group type: EXPERIMENTAL
Intervention: 1250 units of Factor XIII
Number of subjects: 75
Study 16485185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16485185 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII levels < 70 %
Number of subjects: 75
Study 16485185 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII levels >= 70 %
Number of subjects: 75
Study 12587945 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran/melagatran (Exanta)
Number of subjects: 0
Study 12587945 — intervention group
Group type: COMPARATOR
Intervention: enoxaparin
Number of subjects: 0
Study 11304763 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m²/d for 5 days, every 3 weeks)
Number of subjects: 402
Study 11304763 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 402
Study 11304763 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 402
Study 11304763 — intervention group
Group type: COMPARATOR
Intervention: PE (cisplatin and etoposide)
Number of subjects: 402
Study 9240874 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 malnourished children
Number of subjects: 68
Study 9240874 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 malnourished children
Number of subjects: 68
Study 9240874 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68
Study 8422283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 4 weeks
Number of subjects: 33
Study 2442928 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia + indomethacin (E + I)
Number of subjects: 24
Study 2442928 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 24
Study 2442928 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (E)
Number of subjects: 24
Study 31480423 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw garlic consumption (twice or more per week)
Number of subjects: 2011
Study 31480423 — intervention group
Group type: COMPARATOR
Intervention: Low raw garlic intake
Number of subjects: 2011
Study 29231541 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation) at Hegu (LI 4) and Neiguan (PC 6) from 30 min before anesthesia induction to the end of operation.
Number of subjects: 100
Study 29231541 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia group (no electrical stimulation).
Number of subjects: 100
Study 23566071 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sterile topical royal jelly
Number of subjects: 25
Study 23566071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22100606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ω‐3 PUFAs (2gr/day for 12 weeks)
Number of subjects: 20
Study 22100606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20947171 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual refraction (MR)
Number of subjects: 110
Study 20947171 — intervention group
Group type: COMPARATOR
Intervention: Autorefraction (AR)
Number of subjects: 110
Study 20947171 — intervention group
Group type: COMPARATOR
Intervention: Pinhole occluder (PH)
Number of subjects: 110
Study 17618241 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrysofIQ IOL
Number of subjects: 27
Study 17618241 — intervention group
Group type: COMPARATOR
Intervention: AcrysofSingle-Piece IOL
Number of subjects: 27
Study 17176827 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary nitric oxide levels measured through its product nitrite in patients with lichen planus
Number of subjects: 0
Study 17176827 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary nitric oxide levels measured through its product nitrite in patients with recurrent aphthous ulcers
Number of subjects: 0
Study 14595527 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of SSRI drugs (intervention group, n=35)
Number of subjects: 70
Study 14595527 — intervention group
Group type: COMPARATOR
Intervention: No change in treatment (control group, n=35)
Number of subjects: 70
Study 11110743 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention promoting early switch from intravenous to oral acetaminophen
Number of subjects: 30
Study 11110743 — intervention group
Group type: COMPARATOR
Intervention: Control group (all other surgical departments)
Number of subjects: 30
Study 8811469 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE membranes
Number of subjects: 15
Study 8811469 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap procedures
Number of subjects: 15
Study 1326846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 2500 anti‐XaU once daily
Number of subjects: 141
Study 1326846 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 anti‐XaU twice daily
Number of subjects: 141
Study 3890130 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine, 2 g i.v. three times a week
Number of subjects: 28
Study 3890130 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28
Study 3890130 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 28
Study 30301358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand exercise
Number of subjects: 60
Study 30301358 — intervention group
Group type: COMPARATOR
Intervention: Control (maintained daily routine)
Number of subjects: 60
Study 29119719 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Moms intervention (one group session, lessons on a mobile website, and text messages)
Number of subjects: 51
Study 29119719 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 51
Study 29119719 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Moms intervention
Number of subjects: 51
Study 27021779 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulation (HPS)
Number of subjects: 49
Study 24607003 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational vaccine formulations containing dPly alone (10 or 30 μg) or both dPly and PhtD (10 or 30 μg each)
Number of subjects: 156
Study 24607003 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide conjugate-containing formulations
Number of subjects: 156
Study 24607003 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 23-valent pneumococcal polysaccharide vaccine (23PPV) followed by placebo
Number of subjects: 156
Study 23063288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia patients prescribed warfarin
Number of subjects: 0